PYXS
Pyxis Oncology, Inc.
$1.76
+5.39%
$111.5M
No data for this timeframe.
Vol
Market Cap$111.5M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders33 funds
Inst. Value$7.9M
Inst. Activity1 buys / 6 sells
Insider Activity0B / 3S
Insider Net $-$15.9K
SEC Reports3
Press Releases2
Recent Activity
May 14, 2026
SEC
Pyxis Oncology reported Q1 2026 financial results, with a net loss of $23.3M ($0.37/share) vs $21.2M ($0.35/share) in Q1
8-K — Impact 5/10
May 14, 2026
SEC
Pyxis Oncology reported Q1 2026 EPS of -$0.37, missing consensus of -$0.35 by 5.7%. The clinical-stage biotech has $42.5
PRESS-RELEASE — Impact 4/10
May 14, 2026
earnings
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
<p align="center"><em>Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurren
Apr 30, 2026
SEC
Pyxis Oncology filed a DEFA14A notice of internet availability of proxy materials for its 2024 Annual Meeting of Stockho
DEFA14A — Impact 2/10
Mar 24, 2026
Insider
Lewis-Hall Freda C was granted 45,867 shares
Director
Mar 24, 2026
Insider
FLAVIN JOHN L was granted 45,867 shares
Director
Mar 24, 2026
Insider
Palani Santhosh was granted 45,867 shares
Director
Inst.
TORONTO DOMINION BANK — TRIM
50,000 shares ($73.0K)
Price Targets
$7.00
+297.7% upside
Strong Buy
Current $1.76
Low $5.00
Median $7.00
High $9.00
8 analysts
$5.00
$9.00
Analyst Ratings
8Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 5, 2026 | Wedbush | INITIATE | Outperform |
| Mar 24, 2026 | Stifel | MAINTAIN | Buy → Buy |
| Mar 24, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Dec 19, 2025 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Dec 19, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.35 ▲ +2.9% | $-0.39 — $-0.23 | -16% YoY | 8 |
| Next Q | $-0.28 ▲ +1.5% | $-0.37 — $-0.23 | 20% YoY | 8 |
| Current FY | $-1.23 ▲ +1.3% | $-1.51 — $-0.99 | 4% YoY | 8 |
| Next FY | $-1.24 ▲ +2.9% | $-1.69 — $-0.78 | -1% YoY | 8 |
Latest Reports
NEUTRAL
8-K
5/10
Pyxis Oncology reported Q1 2026 financial results, with a net loss of $23.3M ($0.37/share) vs $21.2M ($0.35/share) in Q1
May 14, 2026
NEUTRAL
PRESS-RELEASE
4/10
Pyxis Oncology reported Q1 2026 EPS of -$0.37, missing consensus of -$0.35 by 5.7%. The clinical-stage biotech has $42.5
May 14, 2026
BULLISH
Press
7/10
Pyxis Oncology announced preclinical data showing that a mouse analog of its drug MICVO (maMICVO) demonstrated dose-depe
Apr 17, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $3.0M | — |
| RENAISSANCE TECHNOLOGIES LLC | $1.3M | ADD |
| BlackRock, Inc. | $1.2M | TRIM |
| MARSHALL WACE, LLP | $517.4K | ADD |
| VANGUARD FIDUCIARY TRUST CO | $439.3K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 24, 2026 | Lewis-Hall Freda | A | $0.00 |
| Mar 24, 2026 | FLAVIN JOHN | A | $0.00 |
| Mar 24, 2026 | Palani Santhosh | A | $0.00 |
| Mar 24, 2026 | Cline Darren | A | $0.00 |
| Mar 24, 2026 | HUMPHREY RACHEL | A | $0.00 |
33 institutional holders with $7.9M total value (5,402,389 shares) as of 2026-Q1. Top holders: VANGUARD, RENAISSANCE, BlackRock,. Net selling activity: 6 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 2,033,510 | $3.0M | 37.6% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 888,680 | $1.3M | 16.4% | ADD +26.4% |
| 3 | BlackRock, Inc. | 788,839 | $1.2M | 14.6% | TRIM -26.2% |
| 4 | MARSHALL WACE, LLP | 354,417 | $517.4K | 6.6% | ADD +35.7% |
| 5 | VANGUARD FIDUCIARY TRUST CO | 300,897 | $439.3K | 5.6% | — |
| 6 | STATE STREET CORP | 248,837 | $363.3K | 4.6% | NEAR_EXIT -80.0% |
| 7 | TWO SIGMA INVESTMENTS, LP | 73,300 | $107.0K | 1.4% | DOUBLED +126.9% |
| 8 | MORGAN STANLEY | 69,688 | $101.7K | 1.3% | TRIM -33.4% |
| 9 | PANAGORA ASSET MANAGEMENT INC | 69,424 | $101.4K | 1.3% | — |
| 10 | CITADEL ADVISORS LLC | 67,100 | $98.0K | 1.2% | — |
| 11 | CITADEL ADVISORS LLC | 61,249 | $89.4K | 1.1% | — |
| 12 | STIFEL FINANCIAL CORP | 50,537 | $73.8K | 0.9% | — |
| 13 | TORONTO DOMINION BANK | 50,000 | $73.0K | 0.9% | TRIM -33.3% |
| 14 | BARCLAYS PLC | 49,825 | $72.7K | 0.9% | TRIM -39.0% |
| 15 | GOLDMAN SACHS GROUP INC | 46,920 | $68.5K | 0.9% | — |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 42,300 | $61.8K | 0.8% | — |
| 17 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 41,201 | $60.2K | 0.8% | — |
| 18 | COMMONWEALTH EQUITY SERVICES, LLC | 34,755 | $50.7K | 0.6% | TRIM -35.0% |
| 19 | Point72 Asset Management, L.P. | 32,006 | $46.7K | 0.6% | NEAR_EXIT -83.0% |
| 20 | DIMENSIONAL FUND ADVISORS LP | 25,912 | $37.8K | 0.5% | TRIM -48.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TORONTO DOMINION BANK | TRIM | 75,000 | 50,000 | -33.3% | $73.0K | 2026-Q1 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 188,136 | 32,006 | -83.0% | $46.7K | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 50,066 | 25,912 | -48.2% | $37.8K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 587,851 | 16,807 | -97.1% | $24.5K | 2026-Q1 |
| FEDERATED HERMES, INC. | ADD | 1,894 | 3,181 | +68.0% | $4.6K | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | NEAR_EXIT | 8,227 | 743 | -91.0% | $1.1K | 2026-Q1 |
| CWM, LLC | TRIM | 70 | 34 | -51.4% | $50.00 | 2026-Q1 |
| CWM, LLC | NEAR_EXIT | 414 | 70 | -83.1% | — | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 576,336 | 728,380 | +26.4% | $837.6K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 46,501 | 105,528 | +126.9% | $121.4K | 2025-Q4 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 36,516 | 50,066 | +37.1% | $57.6K | 2025-Q4 |
| COMMONWEALTH EQUITY SERVICES, LLC | TRIM | 61,155 | 39,755 | -35.0% | $45.7K | 2025-Q4 |
| Mirae Asset Global Investments Co., Ltd. | ADD | 2,398 | 3,026 | +26.2% | $3.5K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 285 | 2,285 | +701.8% | $2.6K | 2025-Q4 |
| HRT FINANCIAL LP | DOUBLED | 15,398 | 39,649 | +157.5% | $45.00 | 2025-Q4 |
| BlackRock, Inc. | TRIM | 926,805 | 683,702 | -26.2% | $1.5M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 22,069 | 615,922 | +2690.9% | $1.4M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 417,822 | 576,336 | +37.9% | $1.3M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 160,174 | 106,607 | -33.4% | $236.7K | 2025-Q3 |
| FMR LLC | NEAR_EXIT | 94,846 | 15,455 | -83.7% | $34.3K | 2025-Q3 |
| BARCLAYS PLC | TRIM | 4,854 | 2,961 | -39.0% | $6.6K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 699 | 285 | -59.2% | $633.00 | 2025-Q3 |
| HRT FINANCIAL LP | TRIM | 50,668 | 15,398 | -69.6% | $34.00 | 2025-Q3 |
| CWM, LLC | NEAR_EXIT | 6,536 | 414 | -93.7% | $1.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 582,136 | 417,822 | -28.2% | $459.6K | 2025-Q2 |
9 unique insiders with 13 transactions. Net insider value: -$15.9K ($0.00 bought, $15.9K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 24, 2026 | Lewis-Hall Freda C | Director | AWARD | 45,867 | — | — |
| Mar 24, 2026 | FLAVIN JOHN L | Director | AWARD | 45,867 | — | — |
| Mar 24, 2026 | Palani Santhosh | Director | AWARD | 45,867 | — | — |
| Mar 24, 2026 | Cline Darren S | Director | AWARD | 45,867 | — | — |
| Mar 24, 2026 | HUMPHREY RACHEL | Director | AWARD | 45,867 | — | — |
| Mar 24, 2026 | Metzger Michael A | Director | AWARD | 45,867 | — | — |
| Mar 24, 2026 | Dupont Jakob | Director | AWARD | 45,867 | — | — |
| Mar 24, 2026 | Wadhane Jitendra | Prin Fin & Acct Officer | AWARD | 109,461 | — | — |
| Mar 24, 2026 | Wadhane Jitendra | Prin Fin & Acct Officer | AWARD | 262,635 | — | — |
| Feb 3, 2026 | Civik Thomas | Interim CEO | AWARD | 690,131 | — | — |
| Apr 21, 2025 | HUMPHREY RACHEL | Director | SELL | 13,896 | $1.03 | $14.4K |
| Apr 17, 2025 | HUMPHREY RACHEL | Director | SELL | 200 | $0.9700 | $194.00 |
| Apr 14, 2025 | HUMPHREY RACHEL | Director | SELL | 1,400 | $0.9727 | $1.4K |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 3.7/10.
NEUTRAL
8-K
5/10
Pyxis Oncology reported Q1 2026 financial results, with a net loss of $23.3M ($0.37/share) vs $21.2M
May 14, 2026
NEUTRAL
PRESS-RELEASE
4/10
Pyxis Oncology reported Q1 2026 EPS of -$0.37, missing consensus of -$0.35 by 5.7%. The clinical-sta
May 14, 2026
NEUTRAL
DEFA14A
2/10
Pyxis Oncology filed a DEFA14A notice of internet availability of proxy materials for its 2024 Annua
Apr 30, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 16 analysts: 8 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.00 mean target
+297.7% upside
Strong Buy (1.33)
$5.00 Low
$9.00 High
| Metric | Value |
|---|---|
| Current Price | $1.76 |
| Target Low | $5.00 |
| Target Mean | $7.00 |
| Target Median | $7.00 |
| Target High | $9.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.35 | $-0.39 | $-0.23 | -15.8% | +2.9% | 4↑ 2↓ | $0.0B | -99.2% | 8 |
| Next Q 2026-09-30 |
$-0.28 | $-0.37 | $-0.23 | 19.6% | +1.5% | 4↑ 1↓ | $0.0B | 0.0% | 8 |
| Current FY 2026-12-31 |
$-1.23 | $-1.51 | $-0.99 | 4.3% | +1.3% | 4↑ 4↓ | $0.0B | -99.7% | 8 |
| Next FY 2027-12-31 |
$-1.24 | $-1.69 | $-0.78 | -1.3% | +2.9% | 7↑ 0↓ | $0.0B | 7042.9% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.347 | |
| 7d ago | $-0.350 | +0.003 |
| 30d ago | $-0.358 | +0.010 |
| 60d ago | $-0.375 | +0.028 |
| 90d ago | $-0.332 | -0.015 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 5, 2026 | Wedbush | INITIATE | — | Outperform |
| Mar 24, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 19, 2025 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Dec 19, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 6 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 7 | 6 | 2 | 0 | 0 | 87% | |
| Apr 1, 2026 | 7 | 6 | 2 | 0 | 0 | 87% | |
| Mar 1, 2026 | 7 | 6 | 2 | 0 | 0 | 87% | |
| Feb 1, 2026 | 7 | 6 | 2 | 0 | 0 | 87% | |
| Jan 1, 2026 | 7 | 6 | 2 | 0 | 0 | 87% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 14, 2026
earnings
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
<p align="center"><em>Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
May 13, 2026
other
Pyxis Oncology to Participate in Upcoming Investor Conferences
<p align="left">BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation th
May 13, 2026
earnings_calendar
PYXS Q1 2026 Earnings Before Market Open — 2026-05-13
May 8, 2026
earnings_calendar
PYXS Q1 2026 Earnings Before Market Open — 2026-05-08
May 7, 2026
other
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
<p align="left">BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation th
Apr 17, 2026
fda
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
<p align="center"><em>Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model
Mar 25, 2026
earnings_calendar
PYXS Q4 2025 Earnings After Market Close — 2026-03-25
Mar 23, 2026
earnings
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
<p align="center"><em>Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metast